Black Diamond Therapeutics, Inc vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
8.3
Bullish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
BDTX
High-quality business with 23% return on equity and 32% profit margins.
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $9.86 (+279.1%)
7 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
BDTX
MRK
6.7×
Trailing P/E
31.5×
-2.5×
Forward P/E
11.5×
32.0%
Profit Margin
13.6%
100.0%
Gross Margin
76.6%
22.9%
ROE
—
—
Revenue Growth
4.9%
—
Earnings Growth
—
3.39
Beta
0.28
—
Price / Book
—
$149M
Market Cap
$277.0B
$1 – $5
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →